Uniphar plc

UPR

IE00BJ5FQX74

Pharmaceuticals

Real-time Irish S.E. Other stock markets 16:00:30 20/05/2024 BST			5-day change	1st Jan Change
2.655 ^EUR	-0.38%		+2.12%	-1.67%

05-09	Uniphar says trading in line, reports good start to 2024	AN
05-09	Uniphar Logs Organic Gross Profit Growth in FY23, Affirms FY24 Guidance	MT

Uniphar says trading in line, reports good start to 2024

May 09, 2024 at 08:36 pm

Uniphar PLC - Dublin-based healthcare services company - Issues statement ahead of Thursday's annual general meeting. Reports a good start to 2024, with performance in the first four months in line with the board's expectations. Uniphar says it remains well positioned to deliver organic gross profit growth across each division in line with previous guidance and to deliver expectations for the full year. Also highlights continued progress across all five of its sustainability pillars.

Current stock price: 220.00 pence

12-month change: down 16%

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about Uniphar plc

Uniphar says trading in line, reports good start to 2024	05-09	AN
Uniphar Logs Organic Gross Profit Growth in FY23, Affirms FY24 Guidance	05-09	MT
Uniphar ups full-year dividend as profit falls but revenue climbs	02-27	AN
Uniphar Seeks M&A	02-27	CI
Transcript : Uniphar plc, 2023 Earnings Call, Feb 27, 2024	02-27
Uniphar's FY23 Profit Edges Down; Revenue Grows	02-27	MT
Earnings Flash (UPR.L) UNIPHAR Reports FY23 EPS EUR0.16	02-27	MT
Uniphar plc Recommends Final Dividend, Payable on 14 May 2024	02-27	CI
Uniphar plc Reports Earnings Results for the Full Year Ended December 31, 2023	02-27	CI
Uniphar set to meet annual profit and earnings expectations	01-30	AN
Uniphar plc Announces Executive Changes	01-30	CI
Uniphar plc Announces Resignation of Jeffrey Berkowitz from the Board	01-17	CI
Uniphar non-exec director buys EUR115,000 worth of shares	09/10/23	AN
Uniphar non-exec chair buys EUR200,000 worth of shares	06/10/23	AN
Uniphar executives Rabbette and Dolphin buy shares	04/10/23	AN
Uniphar revenue up on divisional growth; sets out earnings target	14/09/23	AN
Transcript : Uniphar plc, H1 2023 Earnings Call, Sep 14, 2023	14/09/23
Uniphar Posts Drop in H1 Attributable Profit; Revenue Rises	14/09/23	MT
Earnings Flash (UPR.L) UNIPHAR Reports H1 Revenue EUR1.24B	14/09/23	MT
Earnings Flash (UPR.L) UNIPHAR Reports H1 EPS EUR0.06	14/09/23	MT
Uniphar plc Reports Earnings Results for the Half Year Ended June 30, 2023	14/09/23	CI
Uniphar plc Declares Interim Dividend for the Period to 30 June 2023, Payable on 20 October 2023	14/09/23	CI
Uniphar Group Appoints Kay Bonavita as Chief Commercial Officer for Uniphar Logistics to Lead the US Team Based Out of Raleigh, North Carolina	10/08/23	CI
FTSE 100 Closes Down 0.2% as Miners Offset Ocado, Rolls-Royce Jumps	26/07/23	DJ
Uniphar half-year trading in line with expectations	26/07/23	AN

Chart Uniphar plc

Duration

Period

More charts

Company Profile

Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,800, the Group is active in Ireland, the United Kingdom, the Benelux, the Nordics, Germany and the United States. The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar plc represents a strong combination of scale, growth and profitability.

Sector

Pharmaceuticals

Calendar

27/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Uniphar plc

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.665 EUR

Average target price

4.42 EUR

Spread / Average Target

+65.85%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
UNIPHAR PLC	-1.67%	791M
MCKESSON CORPORATION	+21.95%	73.38B
CARDINAL HEALTH, INC.	-1.90%	24.13B
SINOPHARM GROUP CO. LTD.	+7.58%	8.78B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+10.52%	8.59B
HUADONG MEDICINE CO., LTD	-19.80%	8.06B
H. LUNDBECK A/S	+14.16%	5.26B
EBOS GROUP LIMITED	-0.03%	4.21B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+12.13%	4.17B
GALENICA AG	-2.54%	3.89B

Pharmaceuticals Wholesale

Uniphar plc

Equities

UPR

IE00BJ5FQX74

Pharmaceuticals

Uniphar says trading in line, reports good start to 2024

EPS Revisions